Shattuck Labs Announces Key Milestones for SL-325 Program Targeting Inflammatory Diseases
核心洞察
Shattuck Labs anticipates GLP toxicology study data readout for SL-325, a DR3 (搜索) blocking antibody, in Q1 2025, supporting its development for inflammatory diseases (搜索).
The company plans to file an IND for SL-325 in Q3 2025 and initiate a Phase 1 clinical trial in the same quarter, marking significant progress.
Shattuck expects to nominate a lead DR3 (搜索) bispecific development candidate in H2 2025, expanding its pipeline in TNF superfamily receptor therapeutics.
Shattuck Labs (STTK) has set the stage for a pivotal year in 2025 with its DR3 (搜索) blocking antibody program, SL-325, designed to treat inflammatory and immune-related diseases. The company anticipates several key milestones, including the readout of GLP toxicology study data in the first quarter, an IND filing in the third quarter, and the initiation of a Phase 1 clinical trial also in the third quarter of 2025.
These developments underscore Shattuck's focus on pioneering novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors. The company's lead program, SL-325, is a first-in-class DR3 (搜索) antagonist antibody engineered to achieve a more complete blockade of the clinically validated TL1A/DR3 pathway.
Upcoming Milestones for SL-325
Shattuck Labs is strategically positioned to advance SL-325 through critical development phases in the coming year:
- Q1 2025: Preclinical SL-325 data readout from GLP toxicology study in non-human primates (NHPs).
- Q3 2025: Investigational New Drug (IND) filing for SL-325.
- Q3 2025: Initiation of the SL-325 Phase 1 clinical trial.
- H2 2025: Nomination of lead DR3 bispecific development candidate(s).
"We have made considerable progress in the development of our potential first-in-class DR3 (搜索) blocking antibody, SL-325," said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck. "Based on observations from our preclinical, non-human primate (NHP) studies, we remain highly optimistic that SL-325 will achieve a more complete blockade of the clinically validated DR3/TL1A signaling pathway."
Financial Position
As of September 30, 2024, Shattuck Labs reported a strong financial position with approximately $90.1 million in cash, cash equivalents, and investments. The company believes these resources will be sufficient to fund planned operations into 2027, extending beyond the Phase 1 clinical trial of SL-325.
Scientific Presentations
Shattuck Labs is set to present its research at upcoming scientific conferences, including:
- Crohn’s and Colitis Congress: February 6–8, 2025, in San Francisco, CA (poster presentation).
- 20th European Crohn’s and Colitis Organization Congress: February 19–22, 2025, in Berlin, Germany (oral presentation).
J.P. Morgan Healthcare Conference
Shattuck's Chief Executive Officer, Dr. Taylor Schreiber, will present the Company’s Corporate Presentation and participate in scheduled one-on-one investor meetings at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025.
About SL-325
SL-325 is designed to achieve a more complete blockade of the clinically validated TL1A/DR3 (搜索) pathway. Preclinical studies have demonstrated high affinity binding and superior efficacy over TL1A antibodies, providing a rationale for targeting DR3 versus its ligand, TL1A. The drug is currently undergoing GLP toxicology studies in non-human primates.